Ozempic for kidney disease: the FLOW trial dose, the renal cautions, the coverage path

TLDR. The FLOW trial (Perkovic et al, NEJM May 2024) enrolled 3,533 adults with type 2 diabetes and chronic kidney disease and randomized them to semaglutide 1.0 mg weekly (the Ozempic dose) or placebo. The primary composite kidney-event endpoint dropped by 24 percent. Cardiovascular death dropped by 29 percent. All-cause mortality dropped by 20 percent. KDIGO updated its 2024 guideline to incorporate GLP-1 as part of standard care in T2D with CKD. Coverage runs through the existing T2D Part D and commercial pathways. The FLOW dose is the Ozempic dose, not the Wegovy dose.

Chronic kidney disease affects roughly 37 percent of patients with type 2 diabetes. Until 2024, the cornerstone interventions were RAAS blockers (ACE inhibitors or ARBs), SGLT2 inhibitors (per FIDELIO-DKD, EMPA-KIDNEY, and CREDENCE), and glycemic and blood-pressure control. GLP-1 was a useful adjunct for glycemic control without a dedicated kidney-outcome trial. FLOW changed that.

FLOW trial design

• Population: 3,533 adults with T2D and CKD, defined as eGFR 25 to 75 with albumin-to-creatinine ratio 300 mg/g or greater (severe albuminuria) OR eGFR 25 to 50 with ACR 100 to 300 (moderate albuminuria).
• Background therapy: Both arms received guideline-directed care including RAAS blockers (95 percent) and SGLT2 inhibitors (15 percent, growing during the trial).
• Intervention: Semaglutide 1.0 mg weekly versus placebo. Note this is the Ozempic dose, not the Wegovy 2.4 mg dose.
• Primary endpoint: Composite of kidney-failure events (sustained 50 percent or greater eGFR decline, ESKD requiring kidney replacement therapy, kidney-disease death) and cardiovascular death.
• Stopped early: Yes, for efficacy. The DSMC recommended early stop at the interim analysis.
• Median follow-up: 3.4 years.

What the trial reported

Primary composite endpoint: 18.7 percent semaglutide versus 23.2 percent placebo. Hazard ratio 0.76 (95 percent CI 0.66 to 0.88, p less than 0.001). NNT to prevent one major kidney event over 3.4 years: 22.

Component breakdown:

• Sustained 50 percent or greater eGFR decline: HR 0.71 (0.55 to 0.92), significant.
• ESKD requiring kidney replacement therapy: HR 0.80 (0.64 to 1.00), borderline significant.
• Kidney-disease death: HR 0.69 (0.45 to 1.07), trended positive, not significant.
• Cardiovascular death: HR 0.71 (0.56 to 0.89), significant.
• MACE secondary endpoint: HR 0.82 (0.68 to 0.98), significant.
• All-cause mortality: HR 0.80 (0.67 to 0.95), significant.
• Annual eGFR slope: semaglutide group declined 1.16 mL/min/1.73m2 per year more slowly than placebo.

The cardiovascular-death reduction in FLOW (29 percent) is larger than in SELECT (15 percent) for a similar molecule, likely because the CKD-T2D population is at higher baseline CV risk and benefits more in absolute terms.

Why the 1.0 mg dose matters

The dose distinction is important. Ozempic is FDA-approved for T2D at 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg. Wegovy is FDA-approved for obesity at 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. The molecule is the same. The labeled indication and dose ceiling differ.

FLOW used 1.0 mg, the Ozempic mid-range dose. The evidence base for kidney protection at the 1.0 mg dose is direct. The evidence base at the 2.4 mg Wegovy dose for kidney protection is by extrapolation. Many clinicians treat the kidney effect as a class effect that scales with dose, but the trial-grade evidence sits at 1.0 mg.

The practical implication: a T2D patient with CKD who is prescribed Ozempic 1.0 mg gets the evidence-based dose. A T2D patient with obesity and CKD who is prescribed Wegovy 2.4 mg probably also gets the kidney benefit, but the dose-finding question is open.

Renal dosing considerations

Semaglutide is not renally cleared in any clinically meaningful way. The pharmacokinetics are similar across the eGFR range studied in FLOW (down to 25). The label does not require dose adjustment for kidney function above eGFR 15. For ESKD on dialysis, the evidence is limited and the use is increasingly common but largely off-label. See our dialysis and ESRD article for that scenario.

Practical monitoring for kidney patients starting Ozempic:

• Baseline eGFR, creatinine, electrolytes, ACR.
• Recheck at 4 to 8 weeks after dose escalation; nausea and vomiting can cause transient AKI episodes through volume depletion.
• Hold the dose temporarily if severe vomiting or diarrhea develops; restart at a lower step after volume status recovers.
• Monitor for sulfonylurea or insulin hypoglycemia if those agents are co-administered; dose reduction of the insulin or sulfonylurea is usually required.

Coverage and PA

Ozempic for T2D is the most established GLP-1 coverage pathway in 2026. Almost all commercial plans and Medicare Part D plans cover it under T2D PA. Documentation required:

• T2D diagnosis (ICD-10 E11.x).
• CKD diagnosis (N18.x) with documented eGFR and ACR.
• Currently on RAAS blocker (ACE or ARB) or documented contraindication.
• Often: SGLT2 inhibitor first or concurrent; this is a step-therapy expectation on many plans.
• Recent A1C; trial of metformin (or contraindication) documented.

The PA is usually approved on first submission with this documentation in place. Denials are most often due to missing SGLT2 trial documentation, which is now an expected first-line per ADA and KDIGO guidance.

Combination with SGLT2 inhibitors

The current standard of care in T2D with CKD is combined RAAS blocker plus SGLT2 inhibitor plus GLP-1, when all three are tolerated. The mechanisms are complementary, not overlapping. FLOW included background SGLT2 use in 15 percent of patients at baseline, growing through the trial. Subgroup analysis showed similar kidney benefit on semaglutide in patients on or off SGLT2.

For practical purposes:

• Start RAAS blocker as the foundation.
• Add SGLT2 inhibitor next; this is now first-line for CKD progression and CV protection.
• Add GLP-1 (Ozempic 1.0 mg) per FLOW evidence.
• Combination is well-tolerated. Monitor blood pressure, kidney function, and glycemic control during the build.

Programs equipped for CKD-T2D management

9amHealth targets cardiometabolic patients including CKD and has the lab integration needed for ongoing monitoring. Form Health handles the comorbidity PA. Knownwell coordinates with nephrology as part of primary-care-integrated metabolic care. Cash-pay weight-loss specialists (Mochi, Hims) are not appropriate for CKD patients without nephrology coordination.

The albuminuria-specific response

Beyond eGFR and the composite endpoint, FLOW reported a substantial reduction in albuminuria on semaglutide: about 33 percent reduction in UACR at 104 weeks versus baseline, compared to roughly 18 percent on placebo. Albuminuria is both a marker of kidney injury and a driver of progression; the medications that reduce it tend to slow further damage.

For an individual CKD-T2D patient:

• If baseline UACR is 300 to 1,000 mg/g, expect a meaningful drop to lower-albuminuria categories on semaglutide.
• If baseline UACR is over 1,000 mg/g, expect a percentage drop but the patient remains in the high-risk category.
• The albuminuria reduction emerges within 3 to 6 months and is durable through the trial duration.
• Combined with maximally tolerated RAAS blocker and SGLT2 inhibitor, the additive reduction can reclassify many patients from high to moderate kidney-risk categories.

The CKD-T2D treatment build-out in 2026

The pillars of evidence-based CKD-T2D care in 2026:

1. RAAS blocker. ACE inhibitor or ARB, maximally tolerated dose. Decades of evidence in proteinuric CKD. Foundation of the regimen.
2. SGLT2 inhibitor. Empagliflozin or dapagliflozin per EMPA-KIDNEY and DAPA-CKD. Now considered first-line addition for CKD progression and CV protection. Combined effect with RAAS blocker is additive.
3. Non-steroidal MRA. Finerenone per FIDELIO-DKD in T2D with albuminuric CKD. Adds another layer of cardiorenal protection. Often the third agent stacked on RAAS plus SGLT2.
4. GLP-1. Semaglutide per FLOW. Adds glycemic, weight, and cardiometabolic benefits with kidney-protective effect on top of the prior layers.
5. Lifestyle and risk-factor management. Blood-pressure target, statin therapy, smoking cessation, weight management.

The combination of all four pharmacologic layers (RAAS, SGLT2, finerenone, GLP-1) is now standard in advanced CKD-T2D management. Tolerability is the limiting factor. Hypotension, hyperkalemia, and volume depletion need monitoring during the build-out.

What about patients with eGFR 25 to 30

FLOW enrolled down to eGFR 25, but the subgroup with eGFR 25 to 30 was smaller than higher-eGFR strata. The trial showed kidney benefit across the eGFR range studied. For patients with very advanced CKD (eGFR 15 to 25), use is increasingly common but off-label. Nephrology involvement is the standard expectation in this range.

Practical considerations at low eGFR:

• GI side effects from semaglutide can cause transient AKI through volume depletion in patients already volume-sensitive.
• Concurrent SGLT2 inhibitor use becomes more cautious below eGFR 25 (off-label in some products, though dapagliflozin has eGFR 25 cutoff and empagliflozin has eGFR 20 cutoff per their kidney indications).
• RAAS blocker dose may need adjustment at very low eGFR.
• The combination requires close clinical follow-up and lab monitoring.

The transplant-specific considerations

Patients with prior kidney transplant are an emerging GLP-1 population. The clinical pattern:

• Post-transplant weight gain is common (10 to 20 percent at 5 years).
• Many transplant patients have T2D, sometimes new-onset diabetes after transplantation (NODAT).
• The FLOW exclusion of dialysis and transplant patients means evidence-by-extrapolation rather than direct trial evidence.
• Drug interactions with immunosuppressants (tacrolimus, cyclosporine, mycophenolate) are minimal but worth monitoring.
• Transplant-specific clinical teams should be involved in any GLP-1 decision for transplant patients.

For the broader transplant-immunosuppressed condition page, see transplant-immunosuppressed comorbidity guidance.

Frequently asked questions

Should I take Ozempic instead of Wegovy if I have CKD and obesity?

If you have T2D and CKD, the FLOW-evidence-based dose is Ozempic 1.0 mg. If you also have obesity and your CKD is stable, your clinician may consider Wegovy 2.4 mg for the larger weight-loss effect, accepting that the kidney evidence at that dose is by extrapolation. Many patients in this scenario stay on Ozempic 1.0 mg for the kidney indication and add a separate weight-loss-specific approach if more weight reduction is needed.

Does FLOW apply to patients without diabetes?

FLOW was T2D-specific. Whether semaglutide protects kidney function in non-diabetic CKD is not established. Several ongoing trials are exploring this. As of mid-2026, the evidence-based kidney indication for semaglutide is limited to T2D-with-CKD.

Does this work for tirzepatide too?

Tirzepatide does not yet have a completed kidney-outcome trial of similar scale. SURPASS-CVOT will report cardiovascular outcomes in T2D, with some kidney-related secondary endpoints. Most nephrologists treat the kidney benefit as plausibly a class effect, but the evidence sits on semaglutide.

What if my eGFR is below 25?

FLOW excluded eGFR below 25. Use in this range is increasingly common but off-label and based on case series, not phase 3 evidence. ESKD on dialysis was excluded entirely. Patients in this range should pursue treatment only with nephrology involvement.

How long does it take to see kidney benefit?

The eGFR slope difference emerges within the first 6 to 12 months. The composite endpoint divergence in FLOW becomes visible at roughly 12 to 18 months. ACR (albuminuria) improvements appear earlier, within 3 to 6 months.

For the broader Ozempic drug profile, see Ozempic. For the related multi-comorbidity scenario, see T2D with CKD and ASCVD. For the dialysis-specific guidance, see GLP-1 in dialysis and ESRD. For the original FLOW deep-dive, see FLOW trial deep-dive. For the cardiovascular parallel, see Wegovy for cardiovascular secondary prevention.

Citations

• Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). NEJM 2024;391:109-121. nejm.org/doi/full/10.1056/NEJMoa2403347
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105(4S):S117-S314. kidney-international.org/article/S0085-2538(23)00766-4/fulltext
• The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. NEJM 2023;388:117-127. nejm.org/doi/full/10.1056/NEJMoa2204233
• Ozempic prescribing information, Novo Nordisk, current label. accessdata.fda.gov/drugsatfda_docs/label/2024/209637s033lbl.pdf
• American Diabetes Association. Standards of Care in Diabetes 2024, section 11: Chronic Kidney Disease. Diabetes Care 2024;47(Suppl 1):S219-S230. diabetesjournals.org/care/issue/47/Supplement_1